Breast Cancer Center of Excellence
Abstract
The Readiness and Lethality of the Total Force is based in large part on personnel health. Nearly 20% of the active duty force is now female, and breast cancer is the number one cancer in active duty women, far surpassing all other causes of cancer in this population. The Breast Cancer CoE utilizes a multidisciplinary approach for researching breast diseases and breast cancer focused on the military at-risk active duty population in order to enhance Readiness of The Total Force. This multidisciplinary model integrates prevention, screening, early diagnosis, treatment and continuing care, but the project is further unique in the incorporation of advances in risk reduction, biomedical informatics, tissue banking and translational research. The project is based on a Discovery Science paradigm, leveraging high-throughput molecular biology technology and our unique clinically and pathologically well-characterized tissue repository with advances in biomedical informatics leading to hypothesis-generating discoveries that are then tested in hypothesis-driven experiments. In addition to the primary achievement of research objectives, the program educates Federal employees as a benefit to the public they serve through Federal service, through support to civil authorities, and in non-Federal professional and academic collaborations. FY21 Accomplishments: - Accrued 307 breast patients to Breast CoE core protocols - Accrued 128 breast patients to the ORIEN research protocol - Acquired 3,428 new biospecimens at our Breast COE sites to the core tissue protocol - Utilized our biospecimens and data base in support of 28 publications from October 2020 to Present - Performed critical research on young women with breast cancer, and the demographic of African-American women with breast cancer, key cohorts affecting cancer as a readiness issue for the DoD - Developed additional research work with NCI regarding young women with breast cancer in relation to the active duty component PATENT: Recurrence Gene Signature Across Multiple Cancer Types. (International Application #: PCT/US19/49688; entered National Phase on March 3, 2021) Provisional Patent Application “Protein markers for the prognosis of breast cancer progression” Murtha Cancer Center/Research Program Provisional Patent Application “Protein markers for estrogen receptor (ER)-positive-like and estrogen receptor (ER)-negative-like breast cancer” Murtha Cancer Center/Research Program Provisional Patent Application “Protein markers for estrogen receptor (ER)-positive luminal a (LA)-like and luminal b1 (LB1)-like breast cancer” Murtha Cancer Center/Research Program
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2023
- Source ID
- b8a058d278224427cd30b57ec0965c9a